Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
Rhea-AI Summary
Biofrontera (NASDAQ:BFRI), a biopharmaceutical company focused on dermatological products commercialization, has scheduled its Second Quarter 2025 Financial Results announcement for August 13, 2025 after market close.
The company will host a conference call and webcast to discuss the results on Thursday, August 14, 2025, at 10:00 AM ET. Investors can access the call via U.S. toll-free number (1-877-877-1275) or international number (1-412-858-5202).
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BFRI declined 3.37%, reflecting a moderate negative market reaction. This price movement removed approximately $331K from the company's valuation, bringing the market cap to $9M at that time.
Data tracked by StockTitan Argus on the day of publication.
Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am Eastern Time.
Conference Call and Webcast Information
| Event: | Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference Call |
| Date: | Thursday, August 14, 2025 |
| Time: | 10:00am ET |
| Conference Call: | 1-877-877-1275 (U.S.) 1-412-858-5202 (international) |
| Webcast: | Webcast | Second Quarter 2025 Financial Results and Business Update Conference Call |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com
FAQ
When will Biofrontera (BFRI) release Q2 2025 earnings?
How can investors join Biofrontera's Q2 2025 earnings call?
What is Biofrontera's (BFRI) main business focus?
What period will Biofrontera's Q2 2025 earnings report cover?
